Dapagliflozin increases retinal thickness in type 2 diabetic patients as compared with glibenclamide: A randomized controlled trial - 30/11/21
on behalf of
ADDENDA-BHS2 trial investigators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Aim |
In patients with type 2 diabetes mellitus (T2DM) a progressive thinning in the central retinal thickness (CRT) is mainly related to neuroretinal degeneration and occurs before the decline in visual acuity or capillary density. We investigated the change in CRT by optical coherence tomography (OCT) in T2DM patients after 12 weeks of treatment with dapagliflozin or glibenclamide.
Methods |
Ninety-seven patients (57 ± 7 years) with T2DM and clinical or subclinical atherosclerosis were randomized 1:1 to dapagliflozin (10 mg/day) or glibenclamide (5 mg/day) on top of metformin XR 1.5 g/day. OCT was obtained in all patients enrolled in the study, both at the time of randomization and at the end of the study.
Results |
Baseline and post-treatment values of fasting glucose and glycated hemoglobin were equivalent in the two arms. There was no difference in change in diabetic retinopathy status after therapy. The center subfield thickness changed by +2(6)μm in the dapagliflozin group and by -1(7) μm in the glibenclamide group (P = 0.001).
Conclusion |
A short-term treatment with dapagliflozin may increase CRT as compared with equivalent glycemic control with glibenclamide.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Diabetic retinopathy, Optical coherence tomography, SGLT2i, Type 2 diabetes mellitus
Mappa
| Trial registration: NCT02919345 |
Vol 47 - N° 6
Articolo 101280- novembre 2021 Ritorno al numero
Articolo precedente
- Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19
- Luigi Di Filippo, Rebecca De Lorenzo, Clara Sciorati, Annalisa Capobianco, Nicola I. Lorè, Andrea Giustina, Angelo A. Manfredi, Patrizia Rovere-Querini, Caterina Conte
- Euglycaemic diabetic ketosis decompensation under dapagliflozin in a patient with MODY3
- F. Phan, O. Bourron, S. Laroche, A.-C. Jeannin, A. Hartemann
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.